Home/Filings/4/0001209191-20-045144
4//SEC Filing

Sandercock Colin 4

Accession 0001209191-20-045144

CIK 0001645460other

Filed

Aug 4, 8:00 PM ET

Accepted

Aug 5, 4:51 PM ET

Size

14.9 KB

Accession

0001209191-20-045144

Insider Transaction Report

Form 4
Period: 2020-08-03
Sandercock Colin
SVP, GENERAL COUNSEL
Transactions
  • Exercise/Conversion

    Common Stock

    2020-08-03$7.50/sh+6,425$48,18823,550 total
  • Sale

    Common Stock

    2020-08-03$20.00/sh6,425$128,50017,125 total
  • Sale

    Common Stock

    2020-08-04$20.05/sh201$4,03017,125 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-08-04201143,374 total
    Exercise: $7.50Exp: 2024-12-27Common Stock (201 underlying)
  • Exercise/Conversion

    Common Stock

    2020-08-04$7.50/sh+201$1,50817,326 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-08-036,425143,575 total
    Exercise: $7.50Exp: 2024-12-27Common Stock (6,425 underlying)
Footnotes (4)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • [F4]These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018.

Issuer

Cue Biopharma, Inc.

CIK 0001645460

Entity typeother

Related Parties

1
  • filerCIK 0001724870

Filing Metadata

Form type
4
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 4:51 PM ET
Size
14.9 KB